Background: Synovial fibroblasts play a key role in the persistence of inflammation and joint destruction in RA. Cell function and proliferation are highly dependent on availability of nutrients and their metabolism. In the joint, fibroblasts have limited access to nutrients and oxygen within the poorly vascularized hypoxic synovium and yet expansion of fibroblast numbers still occurs. This suggests fibroblasts may adapt their metabolism to this environment and this process may be involved in driving persistence of chronic inflammation.
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We used NMR spectroscopy to assess differences in metabolite fingerprints in fibroblasts from patients with established RA, early arthritis and healthy controls, and determine how cytokine production by fibroblasts relates to their metabolic profile. Methods: Fibroblasts were cultured from synovial biopsies from 6 newly presenting, disease-modifying drug naïve patients with established RA (>12 week symptom duration), 6 healthy controls (HC), and patients with arthritis of 12 weeks duration whose disease resolved (n ¼ 6) or evolved into RA (n ¼ 6) at follow-up. Cell metabolites were extracted for analysis using 1D 1 H-NMR spectroscopy and secreted IL6 measured by ELISA. NMR spectra were analysed using partial least squares discriminant analysis (PLSDA) and partial least squares regression (PLS-R) to correlate the metabolite profiles with 1) IL6 production by fibroblasts and 2) the level of CRP, at the time of synovial biopsy, in the serum of patients whose fibroblasts were being assessed. Results: We were able to distinguish the metabolic profiles of fibroblasts from HC and early RA (sensitivity 67%, specificity 67%), HC and established RA (sensitivity 67%, specificity 50%) and resolving arthritis and early RA (sensitivity 67%, specificity 83%). The IL6 production of fibroblasts from patients with inflammatory arthritis was clearly distinct from that of healthy controls. There was a strong correlation between the metabolic profile of synovial fibroblasts and their IL6 production (P < 0.0001) with several metabolites (in particular citrate, carnosine, pyroglutamate, alanine and lactate) contributing. In patients with inflammatory arthritis the fibroblast metabolic profile correlated strongly (P < 0.0001) with patient serum CRP at the time of synovial biopsy, with several metabolites (in particular cholesterol, fatty acids, leucine, citrate and pyroglutamate) contributing. Conclusion: There was a significant association between the metabolomic fingerprint of synovial fibroblasts and their IL 6 production, raising the possibility that IL6 production drives or is driven by significant changes in metabolism. There was also a significant association between CRP levels in the patients' serum and the metabolic profile of their synovial fibroblasts suggesting that fibroblasts from inflammatory arthritis patients retain their metabolic fingerprint during culture ex vivo and that this is strongly related to systemic measures of inflammation in patients with clinical synovitis. Background: The presence of ectopic lymphoid structures resembling germinal centres within the synovium is a common finding in inflammatory arthritis. Many observations have suggested that these structures are immunologically competent and can support chronic inflammation. Nonetheless, it is still unclear whether the lymphocyte infiltration pattern correlates with specific diagnoses, clinical phenotypes and degree of inflammation in early inflammatory arthritis patients.
The aim of this study is to evaluate the correlation between synovial lymphoid aggregates with clinical and laboratory features in an early inflammatory arthritis cohort. Methods: A cohort of 150 disease-modifying antirheumatic drug-naïve patients with early inflammatory arthritis (<12 months duration, at least 1 swollen joints) has been recruited at Barts and The London Hospital, as part of a multi centred MRC-funded Pathobiology of Early Arthritis Cohort (PEAC) http://www.peac-mrc.mds.qmul.ac.uk/. Baseline disease characteristics assessment included ESR, CRP level, RF, ACPA and 28 joints-disease activity score (DAS28).
Ultrasound-guided synovial biopsy has been obtained for all patients. Sections of paraffin embedded RA synovial tissue were stained with standard Haematoxylin and Eosin (H&E) and graded as either a diffuse or aggregate synovitis. The degree of lymphoid organization was further assessed by immunohistochemical staining of sequentially cut sections. The number of lymphocytic aggregates was counted in each section and graded according to a validated, previously published grading system. Results: Preliminary results show: The presence of lymphocytic aggregates has been found in 42 (28%) patients; Lymphocytic aggregates are associated with increased ESR, CRP and DAS28, as well as RF and ACPA seropositivity (P < 0.05); The number of B cells and plasma cells in the synovium are closely associated in early RA (P < 0.05), suggesting in situ differentiation. Conclusion: Synovial lymphocytes aggregates pattern correlates with inflammatory markers, disease activity, and antibody status in early inflammatory arthritis, therefore reflecting a more aggressive and potentially erosive clinical phenotype. Further studies are needed in order to establish to what extent the presence of lymphocyte aggregates could be used in the future to stratify patients according to prognostic categories and to predict response to treatment. Background: A significant amount of myocardial damage during a myocardial infarction (MI) occurs during the reperfusion stage which is known as ischaemic reperfusion (I/R) injury and can account for up to 50% of cell death. SLE is a condition associated with a high burden of cardiovascular morbidity and mortality, when compared with the matched healthy population. A large proportion of these patients are treated with the anti-malarial drug HCQ and whilst retrospective studies have suggested that SLE patients prescribed HCQ have a reduced risk of suffering an MI, inevitably there are patients who still do. Therefore the purpose of this study is to determine whether HCQ has an effect on I/R injury. Methods: We utilized an established in vitro model simulated ischaemic reperfusion (I/R) injury. Cardiomyocytes were isolated from 1-2 day old rat pups and when beating synchronously were treated with 1-2 mg/ml HCQ and the following day exposed to simulated I/R injury in a hypoxic chamber (argon, 5% CO 2 ) followed by reoxygenation. Apoptosis was assessed using a TUNEL kit and caspase-3 cleavage detected by immunoblot.
Results: Neonatal rat cardiomyocytes treated with HCQ prior to and during simulated I/R injury showed reduced cell death, specifically apoptosis when compared with control cells. This was observed using TUNEL which showed that cells exposed to hypoxia alone saw a 20.7% (S.D. 7.4) increase in TUNEL positivity when compared with cells in optimal conditions. This was further increased to 30.1 % (S.D. 7.0) (P < 0.001) after reoxygenation and in the presence of HCQ was abrogated back down to16.93 % (S.D. 3.0) (P < 0.0001). This was confirmed by an increase in cleaved caspase-3 [0.24 relative to GAPDH (S.D. 0.10) (P < 0.0001)] in cells exposed to simulated I/R injury when compared with cells in optimal conditions [0.03 relative to GAPDH (S.D. 0.03)]. In the presence of HCQ this increase in caspase-3 cleavage was reduced by 54% [0.11 relative to GAPDH (S.D. 0.06) (P < 0.01)]. Correlating with decreased cell death, enhanced ERK phosphorylation in HCQ treated cells was observed in a dosedependent manner. Cells treated with HCQ and exposed to simulated I/R injury were incubated with the ERK inhibitor U1026 and protective effects of HCQ was completely reversed. Additional experiments indicate pre-treatment of cells with HCQ prior to simulated I/R injury leads to the most significant protection and treatment only during the simulated reperfusion stage offers no protection. Conclusion: HCQ is cardioprotective in this in vitro I/R injury model and results suggest this protection is dependent upon up-regulation of ERK phosphorylation. Experiments are now being performed to confirm this observation using an in vivo I/R injury animal model. Disclosure statement: The authors have declared no conflicts of interest. Background: OA is characterized by cartilage degradation and osteophyte formation. Proteinase-activated receptor-2 (PAR-2) has been shown to play an important role in experimental OA as cartilage breakdown is reduced in PAR-2 deficient mice, or by inhibition of this receptor in wild-type (WT) mice (Ferrell WR et al. Ann Rheum Dis 2010; 69:2051-54) . This study examines osteophyte development in murine OA and the extent to which it is influenced by PAR-2 deficiency. Methods: OA was induced in C57Bl/6 mice by destabilization of the medical meniscus (DMM) and osteophyte development assessed by micro computed tomography (mCT, Skyscan 1172, 4.5 mm resolution) of the knee at 3, 7, 14 and 28 days in WT mice (n ¼ 12 per group), and at day 28 in PAR-2 deficient mice (n ¼ 4). Results: In WT mice, osteophytes were identified in 70% of mice by day 7 post DMM and in all mice by day 14. At day 7 most samples had 1 or 2 osteophytes, with some having up to 4 osteophytes by day 14. The number of osteophytes per animal did not increase from day 14 but the osteophytes linearly increased in size and bone content with time (r ¼ 0.7 and 0.76 respectively, both P < 0.0001). By contrast, in the PAR-2 deficient group osteophytes were only present in two mice and these were three orders of magnitude smaller. By day 28, osteophyte volume at 3.54 AE 0.94 x10 7 mm 3 (mean AE SEM) was significantly greater (P < 0.03) in WT compared with PAR-2 deficient mice (2.33 AE 1.5 x10 4 mm 3 ). Consistent with this, osteophyte bone volume in WT was also significantly (P < 0.01) greater than that observed in PAR-2 deficient mice (1.66 AE 0.37 Â 10 7 mm 3 and 1.91 AE 1.26 Â 10 4 mm 3 respectively). However, the percentage of bone per osteophyte was significantly (P < 0.01) less in WT (52 AE 3.4%) compared with PAR-2 deficient mice (81.4 AE 2.7%). Conclusion: Osteophytes develop rapidly in the DMM model of OA, before cartilage degradation is evident. Our previous finding had demonstrated that absence of PAR-2 protects mice from experimental OA. mCT analysis now reveals that the absence of PAR-2 substantially abrogates osteophyte formation in the DMM model, evidencing a key role for this receptor in bone changes associated with OA pathogenesis. Background: The UBE2L3 gene is strongly associated with SLE and multiple autoimmune diseases (RA, JIA, ulcerative colitis, Crohn's disease, coeliac disease and psoriasis). UBE2L3 is a highly specific E2 ubiquitin-conjugating enzyme. Linear ubiquitination is an entirely new form of ubiquitination, whose only known function is controlling activation of NF-kB. The E3 ligase linear ubiquitination chain assembly complex (LUBAC) has been shown to be critical for NF-kB activation following TNF stimulation. However, the role of E2 conjugating enzymes in regulating LUBAC has not been previously elucidated. Methods: UBE2L3 genotype data from the recent SLE GWAS (under review) were imputed up to 1000 genomes level. Using integrated NF-kB luciferase reporter cell line, the effect of overexpression of UBE2L3 in combination with LUBAC components (Sharpin, HOIL-1, HOIP) was compared with other E2 enzymes, or dominant-negative mutant UBE2L3 (C86S) created by site-directed mutagenesis. Signalling pathways were analysed by western blot. Using blood samples from healthy individuals from the St Thomas' Twins Unit stratified by UBE2L3 genotype, B cells and monocytes were isolated by magnetic beads, and stimulated with CD40L or TNF respectively. NF-kB p65 nuclear translocation was visualized and quantified using Imagestream imaging flow cytometer. Results: Data from SLE GWAS identified rs140490 as the probable causal SNP, located at À270 bp of the promoter region of UBE2L3 (P ¼ 8.6 Â 10 À14 ; OR 1.30, 95% CI: 1.21, 1.39). Microarray and western blot studies found that the rs140490 risk allele increased UBE2L3 expression in B cells and monocytes. Overexpression of UBE2L3 in combination with LUBAC led to a massive upregulation in NF-kB activity, both basally and in response to TNF. Our results show that UBE2L3 is the critical E2 conjugating enzyme for LUBAC, and it exerts rate-limiting control over NF-kB activation. Blockade of UBE2L3 via siRNA antagonized TNF signalling by inhibiting phosphorylation and degradation of the NF-kB sequestration protein IkBa. Imagestream analysis of ex vivo human cells showed that UBE2L3/ rs140490 genotype controlled both basal NF-kB activation in healthy human individuals, as well as the sensitivity of NF-kB to CD40 stimulation in B cells and TNF stimulation in monocytes. Conclusion: This is the first study to show that UBE2L3 is a critical ratelimiting enzyme in TNF and CD40 signalling in vivo, and that the major mechanism underlying the function of UBE2L3 is NF-kB activation mediated by LUBAC. This suggests that UBE2L3 is a potential therapeutic target. By tracking NF-kB nuclear translocation in ex vivo cells from individual patients, this is the first demonstration that a specific genetic variant at UBE2L3 affects both basal NF-kB activation and sensitivity of NF-kB to stimulation. Thus rs140490 may have both prognostic implications in autoimmune diseases, as well as predictive value in determining an individual's response to anti-TNF therapy. Disclosure statement: The authors have declared no conflicts of interest.
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